ClinVar Miner

Submissions for variant NM_003000.3(SDHB):c.418G>T (p.Val140Phe)

gnomAD frequency: 0.00003  dbSNP: rs267607032
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 14
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000132167 SCV000187244 pathogenic Hereditary cancer-predisposing syndrome 2022-06-16 criteria provided, single submitter clinical testing The p.V140F pathogenic mutation (also known as c.418G>T), located in coding exon 4 of the SDHB gene, results from a G to T substitution at nucleotide position 418. The valine at codon 140 is replaced by phenylalanine, an amino acid with highly similar properties. In one study, this mutation was detected in a 13-year-old boy diagnosed with an abdominal paraganglioma whose mother (also a carrier) was diagnosed with a thoracic paraganglioma at the age of 14 (Santiago AH et al. J. Pediatr. Endocrinol. Metab., 2010 Apr;23:419-22). In another study, two siblings were found to be carriers of this alteration, a 55-year-old woman and her 49-year-old brother, both of whom were diagnosed with a paraspinal paraganglioma. Their mother, however, was 76 years old and unaffected with cancer, suggesting reduced penetrance. Of note, this family also had a deceased sibling who was diagnosed with a neuroblastoma as an infant, metastatic extra adrenal sympathetic paragangliomas reminiscent of pheochromocytomas as a young adult, and renal cell carcinoma as an adult. It is not known whether this sibling was a carrier of this alteration (Schimke RN et al. Am. J. Med. Genet. A, 2010 Jun;152A:1531-5). A retrospective study looking at genotype-phenotype correlations of SDHB mutation carriers identified 4 patients with this variant; however, only one of these patients had PGL/PCC, again suggesting reduced penetrance (Rijken JA et al. Clin. Genet. 2018 Jan;93(1):60-66). In a recent study, 16 family members of 9 index patients with this mutation were found to carry it; however, only 5 of these family members were found to have disease when they underwent screening for PGL/PCC. This study suggests that the penetrance of p.V140P is 50% at age 38 (Jochmanova I et al. J. Cancer Res. Clin. Oncol., 2017 Aug;143:1421-1435). This variant has also been reported in other cases of childhood metastatic paragangliomas where the carrier parent has been unaffected, again suggesting possible decreased penetrance (Prodanov T et al. Pediatr. Nephrol., 2009 Jun;24:1239-42; Majumdar S et al. Pediatr Blood Cancer, 2010 Mar;54:473-5). In addition, this mutation was detected in an individual with pheochromocytoma whose tumor demonstrated absent SDHB staining on immunohistochemistry (van Nederveen FH et al. Lancet Oncol., 2009 Aug;10:764-71). This alteration has also been identified in 2/27 patients with urinary bladder paraganglioma (Martucci VL et al. Urol. Oncol., 2015 Apr;33:167.e13-20). Based on internal structural analysis, this mutation is anticipated to result in a significant decrease in structural stability (Inaoka DK et al. Int J Mol Sci, 2015 Jul;16:15287-308). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
GeneDx RCV000505751 SCV000235632 pathogenic not provided 2023-11-06 criteria provided, single submitter clinical testing Observed frequently in unrelated patients from different ethnic backgrounds with SDHB-related tumors, several of whom had tumor studies consistent with pathogenic variants in this gene (PMID: 18840642, 19189136, 19576851, 19927285, 20503330, 22588707, 25683602, 29204718, 30050099); Segregates with disease in many affected individuals in several kindreds referred for genetic testing at GeneDx and in published literature (PMID: 20583550, 20503330); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26236513, 20418362, 22588707, 29386252, 34906457, 30050099, 16912137, 20503330, 19927285, 20583550, 19189136, 18840642, 19576851, 22270996, 19802898, 25025441, 25683602, 26273102, 27910947, 27171833, 28374168, 28490599, 28748451, 29204718, 28503760, 29951630, 28152038, 32062700, 32035780, 32741965, 30787465, Hochfelder[abstract], 34703596, 20213850, 34308104, 27535533)
Invitae RCV000627753 SCV000287774 pathogenic Gastrointestinal stromal tumor; Paragangliomas 4; Pheochromocytoma 2023-12-27 criteria provided, single submitter clinical testing This sequence change replaces valine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 140 of the SDHB protein (p.Val140Phe). This variant is present in population databases (rs267607032, gnomAD 0.003%). This missense change has been observed in individuals with paraganglioma (PGL) and malignant PGL (PMID: 16912137, 19189136, 19802898, 19927285, 20503330, 20583550, 26236513). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 18454). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SDHB protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic.
Counsyl RCV000013634 SCV000488516 likely pathogenic Paragangliomas 4 2016-04-28 criteria provided, single submitter clinical testing
Genetic Services Laboratory, University of Chicago RCV000013634 SCV000596999 likely pathogenic Paragangliomas 4 2015-12-07 criteria provided, single submitter clinical testing
Athena Diagnostics RCV000505751 SCV000843761 likely pathogenic not provided 2018-08-07 criteria provided, single submitter clinical testing
Sema4, Sema4 RCV000132167 SCV002527073 pathogenic Hereditary cancer-predisposing syndrome 2021-03-25 criteria provided, single submitter curation
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000505378 SCV002572391 pathogenic Hereditary pheochromocytoma-paraganglioma 2022-08-28 criteria provided, single submitter clinical testing Variant summary: SDHB c.418G>T (p.Val140Phe) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251978 control chromosomes. c.418G>T has been reported in the literature in multiple individuals affected with features of Hereditary Paraganglioma-Pheochromocytoma Syndrome and a reduced penetrance in some families (examples, Brouwers_2006, Meyer-Rochow_2008, Trimmers_2007, Santiago_2010, Lodish_2010, Ricketts_2010, Majumdar_2010, Muth_2012, Prodanov_2009, Schimke_2010, Bayley_2010). These data indicate that the variant is very likely to be associated with disease. No experimental evidence demonstrating an impact on protein function has been ascertained. Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Myriad Genetics, Inc. RCV000013634 SCV004045432 likely pathogenic Paragangliomas 4 2023-04-24 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID:20503330, 20583550, 30050099, 16912137, 19576851]. This variant is expected to disrupt protein structure [Myriad internal data].
Baylor Genetics RCV003473111 SCV004203046 pathogenic Gastrointestinal stromal tumor 2021-05-11 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000013634 SCV004362276 pathogenic Paragangliomas 4 2022-10-25 criteria provided, single submitter clinical testing This missense variant replaces valine with phenylalanine at codon 140 of the SDHB protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in over twenty individuals affected with hereditary paragangliomas/pheochromocytomas, including children (PMID: 16912137, 18840642, 19189136, 19215943, 19927285, 20418362, 20503330, 20583550, 25683602, 26236513, 27171833, 28503760, 29951630, 20503330). This variant has been shown to segregate with disease in two unrelated families (PMID: 20503330, 20583550). Multiple carrier individuals from one of these families were unaffected with SDHB-associated disease. One study has reported detection of this variant in 16 family members of 9 index patients, however, only 5 of these 16 family members were found to have paragangliomas/pheochromocytomas (PMID: 28374168). This study suggested that the penetrance of this variant is 50% at age 38. This variant has been identified in 3/251418 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic.
All of Us Research Program, National Institutes of Health RCV000505378 SCV004822855 pathogenic Hereditary pheochromocytoma-paraganglioma 2023-08-08 criteria provided, single submitter clinical testing This missense variant replaces valine with phenylalanine at codon 140 of the SDHB protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in over twenty individuals affected with hereditary paragangliomas/pheochromocytomas, including children (PMID: 16912137, 18840642, 19189136, 19215943, 19927285, 20418362, 20503330, 20583550, 25683602, 26236513, 27171833, 28503760, 29951630, 20503330). This variant has been shown to segregate with disease in two unrelated families (PMID: 20503330, 20583550). Multiple carrier individuals from one of these families were unaffected with SDHB-associated disease. One study has reported detection of this variant in 16 family members of 9 index patients, however, only 5 of these 16 family members were found to have paragangliomas/pheochromocytomas (PMID: 28374168). This study suggested that the penetrance of this variant is 50% at age 38. This variant has been identified in 3/251418 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic.
OMIM RCV000013634 SCV000033881 pathogenic Paragangliomas 4 2010-06-01 no assertion criteria provided literature only
Section on Medical Neuroendocrinolgy, National Institutes of Health RCV000505378 SCV000599477 pathogenic Hereditary pheochromocytoma-paraganglioma no assertion criteria provided research The penetrance of the disease in SDHB mutations carriers is not 100%, it is about 45-50%. There apparently are other factors contributing to disease development, however those are yet not known.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.